Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Fibrolamellar hepatocellular carcinoma × DT2216 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Fibrolamellar hepatocellular carcinoma 1

Interventions

durvalumab 1 dostarlimab 1 atezolizumab 1 Specimen Handling 1 Sorafenib 1 Irinotecan 1 DT2216 1 Cyclophosphamide 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Children's Oncology Group

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡